Adenosine is an important neuromodulator. Basic cerebral effects of adenosine are exerted by the A 1 adenosine receptor (A 1 AR), which is accessible in vivo by the novel ligand [ 18 F]8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine ([ 18 F]CPFPX) and positron emission tomography (PET). The present study investigates the applicability of kinetic models to describe the cerebral kinetics of [ 18 F]CPFPX in order to quantify A 1 AR density in vivo. Six healthy volunteers underwent dynamic PET scanning and arterial blood sampling after bolus injection of [ 18 F]CPFPX. For quantitative analysis, a standard two-tissue compartment model (2TCM) was compared with a one-tissue compartment model (1TCM) and Logan's graphical analysis (GA). The 2TCM described the cerebral kinetics of [ 18 F]CPFPX significantly better than the 1TCM (in all regions and subjects examined). The estimated values of the regional total distribution volumes (DV t ) correlated strongly between the 2TCM and GA (linear regression r 2 ‫ס‬ 0.99, slope: 1.007). The DV t correlation between the 2TCM and the 1TCM was comparably high, but there was a significant bias towards lower DV t estimates given by the 1TCM (r 2 : 0.99, slope: 0.929). It is concluded that a 2TCM satisfactorily accounts for the cerebral kinetics of [ 18 F]CPFPX. GA represents an attractive alternative method of analysis.
The purine adenosine is an important neuromodulator, beside its central role in cellular energy metabolism and genetic encoding. Four adenosine receptors (A 1 , A 2A , A 2B , and A 3 ) have been cloned and expressed (Dunwiddie and Masino, 2001; Fredholm et al., 2001) . The G i/o protein coupled A 1 adenosine receptor (A 1 AR) is preand postsynaptically localized and expressed throughout the human brain with a dense and heterogeneous distribution (Fastbom et al. 1987a; Svenningsson et al., 1997; Bauer et al., 2003a) . It acts through a number of effectors that inhibit adenylate cyclase activity, reduce Ca 2+ influx and promote a hyperpolarizing outward K + current. Collectively, these actions are tonically neuromodulatory and reduce neurotransmitter release and neuronal exciility.
There are numerous reports on chronic alterations of A 1 AR density in neurological and psychiatric disorders (for review see Dunwiddie and Masino, 2001) . A 1 AR activation is postulated to be protective against glutamate excitotoxicity, as extracellular adenosine levels increase during hypoxia, ischemia, and excessive neuronal activity (Dunwiddie and Masino, 2001; Haas and Selbach, 2000) . A 1 AR density is reduced in the temporal cortex of patients with temporal lobe epilepsy (Glass et al., 1996) as well as in the hippocampus of patients suffering from dementia (Ulas et al., 1993; Deckert et al., 1998) . Thus, its wide distribution and involvement in a variety of physiological and pathological conditions make the A 1 AR an attractive target for in vivo imaging and quantification.
The fluorine-18 labeled A 1 AR antagonist [ 18 F]8cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine ([ 18 F]CPFPX) was recently developed as a PET ligand for in vivo imaging of cerebral A 1 ARs Holschbach et al., 2002) . [ 18 F]CPFPX shows nanomolar in vitro affinity to cloned human A 1 ARs (K D ‫ס‬ 1.26 nmol/L) and a high A 1 AR selectivity over other cerebral receptors including the A 2A AR (K D ‫ס‬ 940 nmol/L). [ 18 F]CPFPX can be synthesized with high radiochemical yield (45%), purity (> 98%) and specific radioactivity (> 270 GBq/mol [> 7.3 Ci/mol]) (Holschbach et al., 2002) . The cerebral distribution of [ 18 F]CPFPX found ex vivo in mice (Holschbach et al., 2002) and rats (Bauer et al., 2003b) as well as in in vivo PET studies in baboons (Boy et al., 1998) corresponded to the known distribution of A 1 ARs. In mice, rats, baboons, and humans, at least two polar, species-specific metabolites are rapidly formed, which are highly unlikely to the cross the blood-brain barrier due to their polarity. In fact, brain homogenate extracts from mice (60 minutes post-injection) demonstrated >98% unchanged ligand (Holschbach et al., 2002) . The first A 1 AR PET study in humans showed a cerebral distribution pattern of [ 18 F] CPFPX that is in agreement with human post mortem A 1 AR autoradiography (Bauer et al., 2003a) .
The present study is intended to evaluate the use of PET kinetic compartment models (one-and two-tissue compartment model) (Mintun et al., 1984) and of Logan's graphical analysis method (Logan et al., 1990) to describe the cerebral kinetics of [ 18 F]CPFPX and to derive quantitative measures of A 1 AR density after a single bolus injection of [ 18 F]CPFPX.
MATERIALS AND METHODS

Subjects
All procedures were approved by the Ethics Committee of the Medical Faculty of the University of Düsseldorf, Germany, and the German Federal Office for Radiation Protection. Six healthy male volunteers (mean age ‫ס‬ 31.89 ± 8.46 years, range ‫ס‬ 21.9-40.5 years) were included after giving written informed consent. Volunteers were screened for history of neurological and psychiatric diseases, head injury, alcohol and substance abuse. A review of current medications excluded the intake of substances interfering with the adenosinergic system (e.g., theophylline). Volunteers avoided caffeine intake for at least 24 hours prior to the PET studies.
To exclude structural brain abnormalities and to define regions of interest (ROI), individual high-resolution magnetic resonance imaging (MRI) data sets were acquired (Magnetom VISION 1.5 T, Siemens, Erlangen, Germany) using a 3D T1weighted magnetization-prepared rapid-acquisition gradientecho sequence (voxel size ‫ס‬ 1x1x1 mm 3 ).
PET Acquisition
Radiosynthesis and formulation of [ 18 F]CPFPX was performed as previously described (Holschbach et al., 2002) . At time of injection the mean specific radioactivity was 72.17 ± 58.74 GBq/mol (range ‫ס‬ 18.66-159.80 GBq/mol) (1.950 ± 1.587 Ci/mol [range ‫ס‬ 0.504 ± 4.319 Ci/mol]).
All PET measurements were performed in 3D mode on a Siemens ECAT EXACT HR+ scanner (Siemens-CTI, Knoxville, TN, USA) equipped with a circular lead shield (Neuroinsert) to reduce scatter radiation from outside the field of view. Scanning took place as the subjects laid supine in a quiet ambience with their heads immobilized in canthomeatal orientation by means of polyurethane foam. A 10 minutes 68 Ge/ 68 Gatransmission scan was acquired to correct for attenuation. Sixty-three slices of 2.425 mm slice thickness (pixel size ‫ס‬ 2 x 2 mm 2 ) were reconstructed per time frame by filtered backprojection (Shepp filter, filter width ‫ס‬ 2.5 mm) after FORE rebinning (Defrise et al., 1997) into 2D sinograms. Data sets were fully corrected for random coincidences, scatter radiation and attenuation. Head positions were permanently monitored and, if necessary, manually corrected using a video system and reference skin marks.
A venous catheter in a forearm vein served for tracer injection. An arterial catheter was inserted into the left distal radial artery under local anesthesia and used for arterial blood sampling. Dynamic PET acquisition (90 minutes) in list mode began with injection of [ 18 F]CPFPX over 20 seconds. Mean injected radioactivity was 273.5 ± 12.0 MBq (range ‫ס‬ 251.6 -284.9 MBq) (7.39 ± 0.32 mCi [range ‫ס‬ 6.80-7.70 mCi]) in a volume of 10 mL sterile saline. The mass of injected CPFPX was 6.54 ± 4.76 nmol (range ‫ס‬ 1.69-14.7 nmol, equal to 0.54-4.73 g CPFPX). During the first 90 seconds after [ 18 F]CPFPX injection, heparinized arterial blood samples (4 mL) were withdrawn every 6 seconds. Thereafter, blood samples were collected at 1: 45, 2, 3, 4, 6, 8, 10, 15, 20, 30, 45, 60, 75 and 90 minutes post-injection. An additional blood sample was taken before [ 18 F]CPFPX administration to assess the fraction of free (unbound to plasma proteins) [ 18 F]CPFPX in plasma (denoted by f 1 ), the extraction fraction of pure [ 18 F]CPFPX (E 0 ) and the plasma caffeine level. List mode data was reframed into a dynamic sequence of 6 x 10 seconds, 3 x 20 seconds, 3 x 30 seconds, 4 x 60 seconds, 3 x 150 seconds, and 15 x 300 seconds frames.
Metabolite Analysis
Centrifugation (1000 x g, 3 minutes) separated plasma from whole blood. Radioactivity in whole blood and plasma samples (500 L), respectively, was measured in an automated gamma counter (1480 WIZARD, Wallac-ADL GmbH, Freiburg, Germany), that is weekly cross-calibrated with the PET scanner using a 68 Ge/ 68 Ga-phantom. Whole blood and plasma timeactivity curves were decay-corrected for the time of injection.
Metabolite analyses were performed in arterial plasma samples taken at 1 minute, 2 minutes and all sampling times thereafter. Aliquots (0.1 mL) of plasma samples were diluted with methanol / acetonitrile (50/50, v/v, 0.1 mL), vortexed for 20 seconds at room temperature, and centrifuged for 1 minute at 20,000 x g. Aliquots (5 L) of the clear supernatant were spotted onto thin-layer chromatography (TLC) plates (SIL G-25 UV 254 glass plates, Macherey-Nagel, Düren, Germany) and developed with ethyl acetate / hexane 75 / 25 (v / v). An InstantImager (Canberra-Packard GmbH, Dreieich, Germany) was used for TLC analysis.
The total radioactivity extraction fraction of each plasma sample (E i ) was determined by spotting 5 L (in triplicate) of the clear supernatant and of the untreated plasma onto a TLC plate, which was read out with the same system. The same procedure was applied to plasma samples obtained before tracer injection to assess the extraction fraction of added
The time course of the fraction of total plasma activity representing the intact ligand (L TLC (t)) was described by fitting the parameters p 1 to p 4 in Eq. 1 (modified from Watabe et al. (2000) ) to the fraction of intact [ 18 F]CPFPX in the plasma samples given by TLC:
For all t < p 1 , L TLC (t) was set to 1 (i.e., 100% unchanged ligand in plasma, usually during the first 1-2 minutes). The additional inclusion of the delay parameter p 1 (restricted to p 1 > 0 minute) and a variable p 3 instead of using a fixed value (as done by Watabe et al. (2000) for [ 11 C]MDL100,907) led to a considerably improved fit of the TLC data in case of
There was a only slight decrease of the total radioactivity extraction fraction over time (falling from virtually 100% to approximately 85-90% at 90 minutes), which precluded to identify all four parameters when fitting Eq. 1 to the time course of the ratio E i /E 0 ( Fig. 1 ). Thus, parameters p 1 and p 3 were empirically set constant (p 1 ‫ס‬ 0 minute and p 3 ‫ס‬ 2), which allowed reasonably good fits (see Fig. 1 ). To correct the TLC data for the time dependent decrease in extraction efficiency, the fits of the TLC data were multiplied with the respective fits to the E i /E 0 ratio. The product was subsequently used to generate metabolite corrected plasma input functions.
Plasma caffeine levels were assessed by HPLC (in triplicate). Individual f 1 values were determined by ultrafiltration (in triplicate).
Image Analyses
An interactive three-dimensional image registration software (MPI-Tool version 3.35, ATV, Erftstadt, Germany) (Pietrzyk et al., 1994) was used to align the individual MRI data sets according to the anterior commissure/posterior commissure line. In each subject, a summed PET image (5.5 to 60 minutes postinjection) was manually co-registered to the realigned MRI. Registration parameters were subsequently applied to each dynamic frame. Errors of manual co-registration using the MPI-Tool software were reported to be below 2 mm (Pietrzyk et al., 1994) , which compares favorable with the spatial resolution of the employed PET scanner (6 mm FWHM). Volumes of interest (VOI) were defined by freehand drawing of polygonal ROI onto the individual MR images and subsequently superimposed onto the PET frames using a dedicated software package (PMOD, version 2.45, PMOD Group, Zurich, Switzerland, www.pmod.com) (Burger and Buck, 1997; Mikolajczyk et al., 1998) . Side-averaged, decay-corrected time-activity curves were generated for the following cerebral regions: dorsal prefrontal cortex (mean total volume of left and right side ‫ס‬ 188.9 ± 22.7 mL), oribitofrontal cortex (40.4 ± 6.5 mL), lateral temporal cortex (129.2 ± 14.7 mL), mesial temporal lobe including amygdala, hippocampus and mesial temporal cortex (19.4 ± 2.0 mL), parietal cortex (87.9 ± 8.1 mL), occipital cortex (94.5 ± 9.9mL), precentral gyrus (35.0 ± 3.7 mL), postcentral gyrus (30.5 ± 3.2 mL), cingulate gyrus (32.0 ± 2.7mL), insula (18.6 ± 2.5 mL), thalamus (10.7 ± 0.6 mL), putamen (8.2 ± 0.8 mL), caudate nucleus (7.9 ± 0.7 mL), cerebellum (112.3 ± 15.6 mL), pons (14.9 ± 1.9 mL) and whole brain (1431.7 ± 88.9 mL).
Kinetic analyses
Compartmental analyses. Two-tissue compartment model. A standard two-tissue compartment model (2TCM) was used for the kinetic analyses of [ 18 F]CPFPX binding to cerebral A 1 ARs after a single bolus injection. The compartment model consists of an arterial plasma input function C p and two tissue compartments. The first tissue compartment represents the combined compartment of the free and the non-specifically bound ligand, which are assumed to equilibrate rapidly so that they can be treated as a single compartment C f+ns (Mintun et al., 1984) . The second tissue compartment C s consists of the ligand specifically bound to A 1 ARs. The unidirectional firstorder rate constants K 1 [mL·mL -1 ·min -1 ] and k 2 [min -1 ] describe the transfer from C p to C f+ns and backwards, respectively. Likewise, k 3 [min -1 ] and k 4 [min -1 ] describe the transfer from C f+ns to C s and backwards, respectively. Eqs. 2 and 3 define k 3 and k 4 :
Parameters k on [(nmol/L) -1 ·min -1 ] and k off [min -1 ] are the association and dissociation constants of the ligand-receptor complex, respectively. B max Ј [nmol/L] is the maximum concentration of available receptors (non-occupied) and f 2 [unitless] is the fraction of free ligand in the tissue (Mintun et al., 1984; Laruelle et al., 1994 ). The regional activity concentration measured by PET (C PET ) summarizes both tissue compartments and a fractional blood volume (V B ) component. This can be expressed as a function of time by:
C a (t) represents the activity concentration in arterial whole blood at a time t. Differential equations (5) and (6) describe the change of ligand concentrations over time in the tissue compartments (Mintun et al., 1984) :
At time of equilibrium t e , i.e., when net transfer between compartments equals zero, the left hand terms of Eq. 5 and Eq. 6 equal zero. Rearrangement of Eqs. 5 and 6 gives the following relationships between the compartmental rate constants and the equilibrium volumes of distribution of both tissue compartments C f+ns (DV f+ns ) and C s (DV s ) : The sum of DV f+ns and DV s is equal to the total volume of distribution of the ligand in tissue (DV t ). Parameter f 1 denotes the fraction of free ligand in plasma.
With f 2 being equal DV -1 f+ns (Abi-Dargham et al., 1994) , insertion of Eqs. 2, 3 and 7 into Eq. 8 yields the definition of the binding potential (BP), which represents the ratio of B max' to the equilibrium dissociation rate constant of the ligand-receptor complex (K D [nmol/L]) (Mintun et al., 1984) :
Using the regional time-activity curves, the metabolitecorrected arterial plasma input curve, and the arterial whole blood time-activity curve, the individual rate constants K 1 , k 2 , k 3 , and k 4 and the regional V B -term were fitted by weighted non-linear regression analyses for each VOI in each subject using the Levenberg-Marquart least squares minimization algorithm as implemented in the PMOD software. The residuals were weighted by the inverse of the variance of the total count rate in each frame. The variance was calculated as the squared standard deviation of the total number of trues within the respective sinogram. The standard deviation of the count rate in each frame i (SD(R i )) was calculated according to the following formula (Eq. 10) (Lammertsma, 2003) , which incorporates an appropriate decay correction factor (F i ) as decay-corrected data was fitted:
where T i represents the total number of trues in a frame of the length L i . Before fitting the individual rate constants, a term for the delay of the arterial input function relative to the tissue response was fitted for the respective subject's whole brain timeactivity curve and kept constant throughout the following analyses. Parameter estimates generated by fitting each subject's whole brain data were used as an initial parameter set for the fitting of the regional data. It was found, that the fitting algorithm converged very reproducibly to the same or a very closely related parameter set, even if, for instance, k 2 and k 3 were varied inversely by one order of magnitude. The standard error of each parameter at convergence (taken from the respective diagonal of the covariance matrix, multiplied by the square root of the degree of freedom adjusted chi square), was taken as a measure of the precision of the estimate and expressed as percentage of the mean (coefficient of variation, %CV). Since the concentration of the total (bound and free) ligand in arterial plasma was used as an input function, binding measures not corrected for the plasma protein bound fraction of the ligand were gained (BP' and DV t Ј). BP and DV t were calculated by dividing BP' and DV t Ј, respectively, by f 1 .
One-tissue compartment model. C f+ns and C s may be kinetically indistinguishable if rapid equilibration occurs between both compartments (Koeppe et al., 1991) . Thus, from an analytical point of view the 2TCM collapses into an one-tissue compartment model (1TCM) containing free, non-specifically and specifically bound ligand in a single tissue compartment. Under this condition, the rate constants k 2 , k 3 , and k 4 can be lumped together to form a composite rate constant (k 2 Ј [min -1 ]) (Koeppe et al., 1991) :
Thus, DV t can be calculated as:
As for the 2TCM, the individual rate constants K 1 and k 2 Ј and the V B -term were fitted for each VOI in each subject using the PMOD software.
Graphical analysis. In addition to the compartment analyses Logan's graphical analysis (GA) (Logan et al., 1990 ) was used to determine DV t . In GA, the DV t is given by the slope of the linear part of the following equation, which describes the dynamic of reversible ligand binding:
with C p (t) being the input function of the free ligand (accounting for f 1 ) in arterial plasma. The time t* determines the time lag after which the intercept term a becomes constant and the relationship between the left hand and the right hand fractional expression linear. t* was determined for each region in each volunteer separately. Prior to GA regional time-activity curves were corrected for the fractional blood volume within each VOI assuming a V B of 5% (Leenders et al., 1990) .
Comparison of the different analyses. The goodness of fit achieved by the 2TCM and the 1TCM was compared by calculating the Akaike Information Criterion (AIC) (Akaike, 1974) and an F-test as described by Landaw and DiStefano (1984) . The DV t values provided by the 2TCM, 1TCM and GA were compared by linear regression analyses. A possible association between the regional binding estimates (DVt' and DVt) and mass of injected CPFPX and plasma caffeine levels, respectively, was explored by Spearman's non-parametric correlation coefficient.
RESULTS
Metabolite analyses. Figure 1 shows a representative example of the time course of the [ 18 F]CPFPX degradation as given by TLC analysis of arterial plasma samples. Subjects' metabolite data could all be well fitted by Eq. 1, the mean parameter being: p 1 ‫ס‬ 2.1 ± 0.9 minute, p 2 ‫ס‬ 0.07 ± 0.02, p 3 ‫ס‬ 0.98 ± 0.28, and p 4 ‫ס‬ 1.78 ± 1.03. The E i /E 0 ratio fell slightly during the 90 minute scan to 0.87 ± 0.03 (Fig 1) . The time course of the E i /E 0 ratio could also be well fitted by Eq. 1 with p 1 and p 3 being constrained to 0 minute and 2, respectively, the mean parameters being: p 2 ‫ס‬ 0.0014 ± 0.0011 and p 4 ‫ס‬ 0.054 ± 0.014. The mean fraction of intact ligand in arterial plasma was 50% at approximately 11 mintues postinjection and less than 10% after approximately 60 minutes. The average f 1 value was 1.18 ± 0.28%.
Cerebral uptake and distribution of [ 18 F]CPFPX. Figure 2 depicts the typical distribution of [ 18 F]CPFPX in the human brain (summed image, 5.5-60 minutes post-injection), which is in agreement with the known in vitro distribution of cerebral A 1 ARs (Fastbom et al. 1987a; Svenningsson et al., 1997; Bauer et al., 2003a) . Figure 3 shows a representative whole brain timeactivity curve and the corresponding arterial input function. [ 18 F]CPFPX showed a rapid brain uptake reaching a maximum of 2.3 ± 0.4% of the injected dose (%ID) (1.6 ± 0.22%ID/L) at 4.2 ± 1.1 minutes post-injection (corrected for an assumed cerebral blood volume of 5%). Depending on the regional A 1 AR density, regional timeactivity curves (V B corrected) peaked approximately 2 to 8 minutes post-injection (later in regions with higher A 1 AR densities), followed by a rapid washout (Fig. 4) .
Kinetic analyses. Two-tissue compartment model. The results of the 2TCM are summarized in Table 1 , representative curve fits are given in Fig. 4 . The regional distribution and magnitude of V B are in good agreement with the known distribution of the regional cerebral blood volume in healthy subjects (Leenders et al., 1990) . The average %CV of the regional V B estimates range 7 to 12% in cortical structures, being higher in the smaller subcortical nuclei (18-20%; exceeding 20% only in five subcortical regions). Similarly, the regional distribution of K 1 values is in good agreement with the regional cerebral perfusion pattern in healthy controls (Leenders et al., 1990) . The average %CV of the K 1 and k 2 estimates range 2-7% (highest in pons; exceeding 10% in no single region) and 7-12%, respectively. Particularly k 2 was less precisely defined in subcortical structures (average %CV ‫ס‬ 14-17%; exceeding 20% 4 times in subcortical regions and 3 times in cortical regions [insula and mesiotemporal]).
The parameter estimations of k 4 and particularly k 3 suffer from low to very low precision (average %CV ranging 16 to 32% and 24 to 59%, respectively), being worst defined in subcortical structures. Neither does k 3 reflect the distribution of cerebral A 1 ARs, nor is the magnitude of k 4 homogeneous across different regions, as might be expected based on their postulated physiological meaning (see Eq. 2 and 3). Similarly, the macro parameter BP' is associated with a high %CV, being on average 9 to 15% in cortical structures (exceeding 20% twice in the insula and once in the mesiotemporal region) and 20 to 24% in subcortical nuclei (exceeding 20% in 7 cases, but remaining always below 40%). The regional BP (and BP') estimates show no clear relationship to the distribution of cerebral A 1 ARs. In fact, the BP (being equivalent to DV s ) accounts for only 25 -38% (mean ‫ס‬ 29%) of the DV t .
In contrast, the %CV of an individual DV t Ј never exceeds 5% except in one case (pons, 9%), mostly ranging from 1-3%. Furthermore, the mean regional estimates of DV t Ј (and consequently DV t ) correspond to the known distribution of cerebral A 1 ARs.
One-tissue compartment model. The results of the 1TCM are given in Table 2 , representative curve fits are displayed in Fig. 4 . The regional distribution of K 1 and V B values is in good agreement with the known distribution of regional cerebral perfusion and regional cerebral blood volume (Leenders et al., 1990) . In absolute terms, V B (ranging 6-8%) was found to be higher than expected (5%). There is a strong correlation between the 1TCM and the 2TCM in regard of the regional K 1 (linear regression: slope ‫ס‬ 0.86, intercept ‫ס‬ -0.003, r 2 ‫ס‬ 0.96) and V B values (linear regression: slope ‫ס‬ 0.94, intercept ‫ס‬ 0.023, r 2 ‫ס‬ 0.83). However, the regional K 1 and V B values yielded from the 1TCM are on average 19.3 ± 5.2% lower and 51.5 ± 19.4% higher, respectively, than the corresponding values given by the 2TCM. The individual estimates of V B given by the 1TCM are associated with a comparable %CV as in the 2TCM (on average ranging 8-13% in cortical regions and 14-16% in subcortical regions, never exceeding 20% in any region). The average %CV of the K 1 and k 2 Ј estimates range from 3 to 6% and from 3 to 7% (always below 10%, exceeding 5% only in cerebellum and pons), respectively. Likewise, the estimates of the DV t' are associated with high estimate precision (%CV always below 5%, exceeding 3% only in cerebellum and pons).
Graphical analysis. The results of the GA are summarized in Table 3 , representative GA plots are shown in Fig. 4 . The time lag t* after which the Logan plot turned Figs. 1-3) . The broken line represents the curve fit given by a one-tissue compartment model, the solid line represents the curve fit of the two-tissue compartment model. Plots on the right show the corresponding graphical analyses. The slopes of the linear regression lines equal the total distribution volume of [ 18 F]CPFPX in the respective region (after blood volume correction assuming a fractional blood volume of 5%). linear ranged between 25 and 35 minutes, except in the cerebellum where t* was 40 minutes in one case and in the caudate nucleus where t* always fell between 15 and 25 minutes.
Comparison between different kinetic analyses. As shown by the AIC (Table 1 and Table 2 ) and in Fig. 4 , the 2TCM fits the cerebral kinetics of [ 18 F]CPFPX considerably better than the 1TCM. Of 90 VOI tested (6 subjects x 15 VOI per subject), this difference is significant in all regions (F test, all p < 0.001, except insula VOI in one volunteer: p < 0.003).
The results of the linear regression analyses between the individual DV t Ј and DV t values, respectively, given by the different analyses are summarized in Table 4 . As shown in Fig. 5 , the 1TCM analysis considerably underestimates DV t Ј (and consequently DV t ) compared to the 2TCM. Depending on the absolute value of DV t Ј and DV t , the mean regional underestimation ranges between 5.4% (putamen; mean absolute DV t underestimation ‫ס‬ 4.4) and 17.5% (cerebellum; mean absolute DV t underestimation ‫ס‬ 7.2). In contrast, the linear regression fits between the DV t' and DV t values, respectively, given by the GA and the 2TCM show only a minimal deviation from the line of identity (see Table 4 : barely significantly y-axis intercept in the regression DV t GA vs. DV t 2TCM, while the regression slope is not different from 1). Consequently, the maximum mean regional deviations be-tween the DV t values given by the GA and the 2TCM are rather small, ranging between -5.9% [-2.5 DV t units] in the pons and 3.3% [2.1 DV t units] in the insula.
The mass of injected CPFPX had no effect on the regional binding parameters DVtЈ and DVt, neither in any region nor in any analysis method. The average plasma caffeine level of the included normal volunteers after requested 24h caffeine abstinence was 0.26 ± 0.14 mg/L (range: 0.13-0.44 mg/L) (for comparison: resorption of 100 mg caffeine, corresponding to one cup of coffee, would lead to a peak plasma caffeine level of approximately 2.5 mg/L). No correlation was found between plasma caffeine levels and binding parameters.
DISCUSSION
The present study is intended to evaluate the applicability of standard compartment models (1TCM and 2TCM) and of Logan's GA (Logan et al., 1990) to quantitatively describe the cerebral kinetics of [ 18 F]CPFPX. [ 18 F]CPFPX is the first PET ligand that has successfully been applied to image A 1 ARs in the human brain in vivo (Bauer et al., 2003a) . It shows several characteristics that make it a promising ligand for the quantitative assessment of cerebral A 1 ARs: Its cerebral uptake is reversible, peaks rapidly and is in accordance with the in vitro distribution of A 1 ARs (Fastbom et al. 1987a; Svenningsson Bauer et al., 2003a) . [ 18 F]CPFPX metabolites are considerably more polar and highly unlikely to cross the blood-brain barrier. Brain homogenate extracts in mice demonstrated >98% unchanged ligand at 60 minutes post-injection (Holschbach et al., 2002) . The maximum brain uptake of [ 18 F]CPFPX, approximately 2.3%ID, permits dynamic PET studies with adequate image characteristics. The long physical half-life of fluorine-18 (110 minutes) allows a reliable determination of the metabolite-corrected plasma input function at later time points. The 2TCM fitted the experimental data significantly better than the 1TCM in all regions of all subjects examined. However, due to the high correlation between individual rate constants the 2TCM suffered from high standard errors of the individual parameter estimates, particularly with regard to k 3 and k 4 , and the derived macro parameter BP'. The relative long scan duration of 90 minutes as compared to 60 minutes and the application of residual weighting had only a moderate beneficial impact on estimate precision. A common method to improve the identifiability of individual parameters is to constrain parameters (e.g., k 4 ‫ס(‬ k off ) or the ratio K 1 /k 2 , equal to f 1 DV f+ns ) in all brain regions to a reasonable constant value, assuming that they are homogenous throughout the brain. Since at this stage there is no reli-able estimate of k 4 , the 2TCM cannot be constrained by using a fixed k 4 .
In vitro animal studies in commonly used laboratory animals (Fastbom et al. 1987b) and PET studies in primates using the A 1 AR ligands [ 18 F]CPFPX (Boy et al., 1998) and [ 11 C]KF15372 (Wakabayashi et al., 2000) showed a high cerebellar A 1 AR density. In contrast, human post mortem autoradiographic studies (Fastbom et al. 1987a; Svenningsson et al., 1997; Bauer et al., 2003a) and PET studies (Bauer et al., 2003a) displayed an overall considerably lower density of A 1 ARs in the cerebellum. Nevertheless, own preliminary bolus/infusion displacement studies in humans showed a specific [ 18 F]CPFPX binding even in regions with lowest binding, which is in agreement with A 1 AR PET studies in monkeys and cats using [ 11 C]KF15372 (Wakabayashi et al., 2000) and [ 11 C]MDPX (Shimada et al., 2002) , respectively. From these studies it can estimated that 25-30% of the cerebellar DV t constitutes specific binding. Under similar circumstances, Watabe et al. (2000) were able to successfully quantify the binding of [ 11 C]MDL100,907 to 5-HT 2A receptors by using a constrained 2TCM (called 2T' in their study), in which the K 1 /k 2 ratio was constrained to the estimate of the DV f+ns of the cerebellum. The latter estimate has been generated by fitting a 2TCM to the data of the cerebellum, where a low level of displaceable binding was found. In case of [ 18 F]CPFPX, DV f+ns Ј ‫ס(‬ K 1 /k 2 ) accounted for approximately 70% of the cerebellar DV t Ј (Table 1) , which could be in accordance with our preliminary displacement studies. However, this finding does most likely not reflect a reliable estimate of the cerebellar DV f+ns Ј, since a relationship of approximately 30:70 of specific:non-specific binding was given by the 2TCM in merely all regions, regardless of the known regional A 1 AR density. This clearly indicates that the BP' estimates and the derived BP value do not reflect the amount of specific binding. Alternative approaches to achieve a quantification of the BP include a dualinjection protocol with subsequent injections of high and low specific radioactivities and a bolus/infusion protocol with displacement. The pharmacological and radiochemical characteristics of [ 18 F]CPFPX appear to be particularly well suited to the latter approach. The 2TCM analyses resulted in highly precise estimates of the DV t Ј (and consequently DV t ). The same was true for the 1TCM, which, however, gave significantly negatively biased estimates due to its poor fit. In contrast, the GA provided DV t values, that were least biased in comparison to the 2TCM. The largest mean regional deviations occurred in pons (-5.9%) and insula (+3.3%). This might be explained by two reasons. Firstly, all regions were corrected for an assumed homogenous V B component of 5%, which differs from the invasive estimates of 3.8% for pons and 6.5% for insula. Thus, the data of pons and insula might be slightly over-and under-corrected, respectively. Neglecting V B in GA leads to an overestimation of the DV t compared to the 2TCM of approximately 5-12% (depending on regional V B and DV t ). Region-specific V B values could be assumed in order to minimize this bias. Secondly, it is well recog-nized that the Logan's GA method itself is affected by a negative bias in regions with high noise levels (Logan et al., 2001; Slifstein et al., 2000) , which additionally might explain the negative bias in small and/or low-binding regions (e.g., pons: -5.9%, cerebellum: -4.3%, caudate nucleus: -3.5%). Several attempt have been made to minimize this bias (Logan et al., 2001; Ichise et al., 2002) . Despite these limitations, GA (or a less biased method (Logan et al., 2001; Ichise et al., 2002) is the favored approach because it is computational simple and also applicable on a pixel-level, which allows it to generate parametric images that are amenable to pixel-bypixel statistical mapping.
At this stage, DV t appears to be the most valid measure to assess the A 1 AR density in vivo with [ 18 F]CPFPX PET. Because DV t summarizes both specific and nonspecific binding, it reflects relative changes of the A 1 AR density in an attenuated manner, whereby the degree of attenuation is proportional to the regional DV s /DV t ratio. Preliminary [ 18 F]CPFPX displacement studies in humans demonstrate that specific binding accounts for at least 60% of the total cortical binding. A 10% change of receptor density would then translate into a 6% change of DV t .
Theoretically, DV t is superior to DV t Ј as an outcome measure, because of its independence from betweensubject or between-condition f 1 variations. However, the determination of f 1 in the magnitude of 1-2% (as in case of [ 18 F]CPFPX) is technically challenging and threatened by a significant measurement inaccuracy. Therefore, at this stage it is difficult to infer, if a f 1 correction is advantageously, e.g. in a diagnostic scenario: We found that there is a weak relationship between DV t Ј and f 1 in the present study group (r ≈ 0.45-0.59) which leads to a slight decrease of the variation of the regional DV t compared to DV t Ј (2TCM, mean regional coefficient of variation, DV t Ј: 29.0%, DV t : 26.8%). This does not necessarily imply, that the slightly lower variation of the DV t enables a better discrimination between two subject groups with different A 1 AR densities. In fact, the higher variation of the DV t Ј might reflect the true variation caused by unknown factors more closely. Thus the exploration of confounding variables as for example age and caffeine consumption might help to decide, whether a f 1 correction is favorably, since the A 1 AR density can be expected to vary with both age (Cheng et al., 2000; Cunha et al., 2001) and chronic caffeine consumption (Shi and Daly, 1999) .
Moreover, the use of DV t' and DV for inter-individual comparisons relies on the assumption, that DV f+ns is reasonably constant across subjects. Although this can be hardly verified in every subject studied, it can be shown by representative pre-blocking or displacement studies.
In conclusion, [ 18 F]CPFPX shows promising in vivo characteristics as a PET ligand for quantification of FIG. 5. Correlation Between DV t Values Provided by 2TCM, 1TCM and GA. The scatter plot at the top shows the correlation between for the DV t values provided by the 1TCM and the 2TCM analysis. The corresponding correlation between GA and 2TCM is shown below. The dotted lines represent unity. For regression parameters see Table 4 . cerebral A 1 ARs. A 2TCM satisfactorily accounts for the cerebral kinetics of [ 18 F]CPFPX, although individual tissue compartments could not be separated using a standard 2TCM. Logan's GA is an attractive alternative method of analysis.
